Bacillus calmette-guerin substrain connaught live antigen is intravesically administered for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR). The solution contains live, attenuated strain of Mycobacterium bovis. It is prepared from the Connaught strain of Bacillus Calmette and Guérin.

Synonyms

BCG, Live, Connaught Strain

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Theracys	Injection, powder, lyophilized, for solution	81 mg/3mL	Intravesical	Sanofi Pasteur Limited	2011-07-22	2017-05-08

Categories

UNII

5H5854UBMZ

CAS number

Not Available

Pharmacology

Indication

Indicated for intravesical use in the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR).

Associated Conditions

Associated Therapies

Salvage therapy

Pharmacodynamics

Not Available

Mechanism of action

Not Available

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half life

Not Available

Clearance

Not Available

Toxicity

Not Available

Affected organisms

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction
2-Methoxyethanol	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with 2-Methoxyethanol.
2-Methoxyethanol	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with 2-Methoxyethanol.
6-Deoxyerythronolide B	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with 6-Deoxyerythronolide B.
9-(N-methyl-L-isoleucine)-cyclosporin A	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.
9-(N-methyl-L-isoleucine)-cyclosporin A	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Abatacept.
Abatacept	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Abatacept.
Abetimus	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Abetimus.
Abetimus	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Abetimus.
Acetyl sulfisoxazole	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Acetyl sulfisoxazole.

Food Interactions

Not Available

References

General References

Not Available

External Links

PubChem Substance: 347910910

AHFS Codes

80:12.00 — Vaccines

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
3	Not Yet Recruiting	Treatment	Bladder Cancers	1
3	Recruiting	Treatment	Bladder Cancers	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage forms

Form	Route	Strength
Injection, powder, lyophilized, for solution	Intravesical	81 mg/3mL

Prices

Not Available

Patents

Not Available

Properties

State: Not Available
Experimental Properties: Not Available

Taxonomy

Classification: Not classified

Drug created on December 01, 2015 13:04 / Updated on January 22, 2019 17:57